🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you to Mitsubishi Tanabe Pharma America, Eikonizo Therapeutics, Joe and Laura Collins, PTC Therapeutics, and the Phi Delta Theta Alumni Club of Metro Detroit for sponsoring #LiveLikeLou's biennial #ALS Research Symposium in Ann Arbor! We have 115+ attendees learning, collaborating, and networking to advance #alsresearch.

Eikonizo Therapeutics is taking it on the road this month to showcase the breadth of our data across #neurodegenerative diseases, including #ALS, #FTD and #Parkinsons. Stop by our posters at #SfN24 in Chicago on 10/9 and at #NEALSMtg in FL on 10/23 to learn more! Society for Neuroscience (SfN) NEALS Consortium

Eikonizo Therapeutics researcher Rebecca James (Rebecca James) is on site at #SfN24 in Chicago, ready to discuss our data in #Parkinsons disease. Stop by poster #D19 from 1-4pm CT today and say hi!

We are looking forward to sharing updates on our research tomorrow at the #ALSResearchSymposium. Thanks for inviting us ALS ONE team! More info on the 7th Annual ALS ONE Research Symposium can be found here: alsoneresearchsymposium.org #ALS

Eikonizo Therapeutics ALS ONE Great to see so many friends at #alsmndsymp this weekend! Thanks Tonya Gilbert for sharing the latest on our lead program, EKZ-102!

We’re thrilled to announce an investment by Novo Nordisk which will support development of our lead candidate EKZ-102 for ALS and enable the advancement of our novel HDAC6 inhibitors as potential disease-modifying therapeutics for cardiorenal disease. businesswire.com/news/home/2024…

Today we also announced key additions to strengthen our leadership, including Tom Hughes, who joins our Board, as well as Rich Fisher as CSO, Jim Luterman as EVP, Development and Jon Graves as VP, Finance and Controller. Learn more about our team here: eikonizo.com/our-team/

Eikonizo Therapeutics Receives Equity Investment From Novo Nordisk finsmes.com/2024/12/eikoni…

Novo Nordisk invests in Eikonizo Therapeutics Therapeutics thepharmaletter.com/novo-nordisk-i…

Eikonizo Therapeutics team will be kicking off the new year with meetings in SF during the 43rd Annual J.P. Morgan Healthcare Conference #JPM2025 ! We are excited to discuss our progress and upcoming milestones. Learn more here: eikonizo.com #JPMorgan #HDACinhibitor

The Eikonizo Therapeutics team was out and about in SF for the J.P. Morgan Healthcare Conference. Hope you gave Rick Lundberg and team a wave if you saw them trekking around Union Sq! #JPMorgan #HDAC6inhibitor

Our CSO Richard Fisher was on site at the 15th annual California #ALS Research Summit in SF last week. Sponsored by the ALS Network, this annual event provides an opportunity for experts in the field to share the latest advancements in #ALSresearch. #HDAC6inhibitor

Today is #NationalWearRedDay established by American Heart Association to raise awareness of #CardiovasularDisease – the #1 killer of women. DYK, according to @ACC women are at higher risk of #HFpEF, a type of heart failure with limited effective treatment options, than men? GoRedforWomen

Work hard, play hard! Eikonizo Therapeutics prides itself on being a team-oriented and fun place to work, as these pics from our recent social gaming outing at #Level99 can attest. #TeamBuilding #WorkHardPlayHard

Eikonizo Therapeutics Clinical Advisor Angela Genge AngelaGenge, Director of the ALS Center at McGill University, presented an overview of current #ALS clinical trials and innovative therapeutics today at #ADPD2025 in #Vienna. linkedin.com/feed/update/ur…

This week through May 11 are #HeartFailureAwarenessDays Eikonizo’s HDAC6 inhibitor platform has the potential to address intracellular transport and proteostasis, two key drivers of cardiorenal disease and heart failure. escardio.org/Sub-specialty-… European Society of Cardiology #HFA_ESC

It's Friday and Day 2 of the Convergence Forum in beautiful Chatham, MA! Our CEO Rick Lundberg is on site meeting with industry leaders and future collaborators. Learn more about Eikonizo's science and programs here: eikonizo.com/our-science/

Eikonizo’s CSO Richard Fisher was honored to present our findings in his presentation "Development of EKZ-102, a CNS-Penetrant Small Molecule HDAC6 Inhibitor as a Potential first-in-class Disease Modifying Therapeutic for ALS" at the ALS Drug Development Summit today in Boston.

Excited to have our CEO Rick Lundberg attend #BIO2025 this week — connecting with fellow innovators and potential partners shaping the future of biotech. If you’re in Boston and want to talk science, strategy, or collaboration, let’s connect! #LifeSciences #Innovation